A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
| Autor: | Sharma, S. *, Kemeny, N., Kelsen, D.P., Ilson, D., O’Reilly, E., Zaknoen, S., Baum, C., Statkevich, P., Hollywood, E., Zhu, Y., Saltz, L.B. |
|---|---|
| Zdroj: | In Annals of Oncology July 2002 13(7):1067-1071 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|